Bone-building drugs double the risk of esophageal cancer, but the risk is still smallInformation on Bone-building drugs double the risk of esophageal cancer, but the risk is still small under Bone Disorders section of the Health Articles & Reviews; The family of bone-building drugs that includes Fosamax, Actonel and Boniva can double the risk of developing throat cancer, researchers reported Thursday in the latest ... |
 |
|
Bone-building drugs double the risk of esophageal cancer, but the risk is still small
by Elizabeth_Gravitt 09-04-2010, 01:45 AM
The family of bone-building drugs that includes Fosamax, Actonel and Boniva can double the risk of developing throat cancer, researchers reported Thursday in the latest development in what has become a confusing discussion. Other studies have reported no increase, but even if the newest finding is correct, the risk is still quite small--about two cases per 1,000 people between age 60 and 79 ...
More... |
Views 8
Comments 0
|
|
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
Linear Mode
